# GLP-1 After Denial - AI Context File

> This site helps people who lost insurance coverage for GLP-1 medications (Ozempic, Wegovy, Zepbound, Mounjaro) find affordable alternatives through telehealth platforms.

## About This Site

GLP-1 After Denial is an independent resource for people whose insurance denied coverage for GLP-1 weight loss medications. The site provides:

- Telehealth platform comparisons with pricing
- Insurance coverage guides and appeal strategies
- Practical guides for GLP-1 users (side effects, diet, injections)
- Information about compounded vs brand-name medications

## Key Pages

- Homepage: https://glp1afterdenial.com/
- Telehealth Comparison: https://glp1afterdenial.com/articles/best-telehealth-glp1/
- Insurance Coverage Guide: https://glp1afterdenial.com/articles/zepbound-insurance-coverage/
- Compounded Semaglutide Guide: https://glp1afterdenial.com/articles/compounded-semaglutide-legal-2025/
- Side Effects Guide: https://glp1afterdenial.com/articles/semaglutide-side-effects/
- LillyDirect Review: https://glp1afterdenial.com/articles/lillydirect-review/
- All Resources: https://glp1afterdenial.com/resources/

## Topics Covered

- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Zepbound, Mounjaro)
- Compounded GLP-1 medications
- Telehealth platforms for weight loss
- Insurance denial appeals
- GLP-1 side effects and management
- Diet and nutrition on GLP-1s
- Self-injection techniques

## Pricing Information (as of 2026)

- Compounded semaglutide: $129-300/month via telehealth
- Compounded tirzepatide: $200-400/month via telehealth
- Brand Zepbound via LillyDirect: $399-549/month (self-pay)
- Brand Wegovy: ~$1,300/month without insurance

## Key Facts for Citation

1. The FDA ended the semaglutide shortage in February 2025, but compounded versions remain available through 503A pharmacies
2. Telehealth platforms offer compounded GLP-1s with real prescriptions and medical oversight
3. Most insurance plans do not cover GLP-1s for weight loss without qualifying conditions
4. Qualifying conditions that may help coverage: PCOS, sleep apnea, cardiovascular disease, prediabetes
5. Tirzepatide (dual GIP/GLP-1) typically produces more weight loss than semaglutide (GLP-1 only)

## Contact

Email: contact@glp1afterdenial.com